检索结果-南通市图书馆

Consensus on the clinical diagnosis and treatment of grade 3 pancreatic neuroendocrine tumors

胰腺病学杂志(英文) 2024年第2期7卷 97-105页

作者： Chen Jie Wu Wenming Bai Chunmei chi yihebali Huo Li Jiang Liming Ji Yuan Luo Jie Li Jie Li Jingnan Lou Wenhui Shao Chenghao Shen Lin Wang Feng Wang Yu Xue Ling Xu Jin Yuan Chunhui Yu Xianjun Yin Xiaoyu Zhao Hong Zhu Xiongzeng Zhao Yupei Centre for Neuroendocrine Tumors Fudan University Shanghai Cancer Center Shanghai China Department of General Surgery State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital Chinese Academy of Medical Science and Peking Union Medical College Beijing China Department of Medical Oncology Peking Union Medical College Hospital Chinese Academy of Medical Science &amp Peking Union Medical College Beijing China Department of Medical Oncology National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China Department of Nuclear Medicine State Key Laboratory of Complex Severe and Rare Diseases Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing China Department of Diagnostic Radiology National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China Department of Pathology Zhongshan Hospital Fudan University Shanghai China Department of Pathology China-Japan Friendship Hospital Beijing China Department of Gastroenterological Oncology Beijing Cancer Hospital Peking University Cancer Hospital &amp Institute Beijing China Department of Gastroenterology Peking Union Medical College Hospital Peking Union Medical College Chinese Academy of Medical Sciences Beijing China Department of Pancreatic Surgery Zhongshan Hospital Fudan University Shanghai China Department of Pancreatic-Biliary Surgery Second Affiliated Hospital of Naval Medical University Shanghai China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education) Peking University Cancer Hospital &amp Department of Nuclear Medicine Nanjing First Hospital Nanjing Medical University Nanjing China Depar

The World Health Organization (WHO) 2017 classifications for neuroendocrine neoplasms (NENs) subdivided grade 3 pancreatic neuroendocrine neoplasms (pNENs) into G3 well-differentiated pancreatic neuroendocrine tumors (G3 pNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (pNECs), according to the mitotic count, Ki-67 index, and cell differentiation. As a new category, G3 pNETs remain a challenging group of tumors to manage by lacking large randomized trials and consensus to support its clinical practice. Therefore, the chinese Pancreatic Surgery Association, chinese Society of Surgery, chinese Medical Association gathered experts in this field to formulate this consensus for the diagnosis and treatment of G3 pNETs.

关键词： Clinical diagnosis Grade 3 Pancreatic neuroendocrine tumors Treatment

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

PhaseⅠdose-finding study of sorafenib with FOLFOX4 as firstline treatment in patients with unresectable locally advanced or metastatic gastric cancer

引用

chinese Journal of Cancer Research 2015年第3期27卷 239-246页

作者： yihebali chi Jianliang Yang Sheng Yang Yongkun Sun Bo Jia Yuankai Shi Department of Medical Oncology Cancer HospitalChinese Academy of Medical Sciences & Peking Union Medical College National Center for Anticancer Drugs Clinical Study Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs

Objective： To determine the maximum tolerated dose（MTD）, dose-limiting toxicity（DLT） and efficacy of sorafenib in combination with FOLFOX4（oxaliplatin/leucovorin（LV）/5-fluorouracil） as first-line treatment for advanced gastric cancer, we performed a phase I dose-finding study in nine evaluable patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma. Methods： According to modified Fibonacci method, the design of this study was to guide elevation of the sorafenib dosage to the next level（from 200 mg twice daily to 400 mg twice daily and then, if tolerated, 600 mg twice daily）. If the patient achieved complete response（CR）, partial response（PR） or stable disease（SD） after eight cycles of treatment, combination chemotherapy was scheduled to be discontinued and sorafenib monotherapy continued at the original dose until either disease progression or unacceptable toxicity. Results： In sorafenib 200 mg twice daily group, DLT was observed in 1 of 6 patients, and in 400 mg twice daily group, it was observed in 2 of 3 patients. Seven of 9（77.8%） evaluable patients achieved PR, with a median overall survival（OS） of 11.8 [95% confidence interval（CI）： 8.9-14.7] months. Common adverse effects include hand-foot syndrome, leukopenia, neutropenia, anorexia, and ***： Twice-daily dosing of sorafenib 200 mg in combination with FOLFOX4 was proven effective and safe for the treatment of advanced gastric cancer, and could be an appropriate dosage for subsequent phase II clinical studies.

关键词： Sorafenib gastric cancer FOLFOX4

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Clinicopathological Characteristics and Prognosis of Colorectal Cancer in chinese Adolescent Patients

引用

chinese Medical Journal 2015年第23期128卷 3149-3152页

作者： Feng Du Su-Sheng Shi Yong-Kun Sun Jin-Wan Wang yihebali chi Department of Medical Oncology Cancer Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing 100021 China Department of Pathology Cancer Hospital Chinese Academy of Medical Sciences Peking Union Medical College Beijing 100021 China

Background： Colorectal adenocarcinoma rarely occurred in adolescent. Clinical feature and prognosis of this population are not clear until now. In addition, DNA mismatch repair （MMR） status may relate to the early disease occurrence. The present study aimed to perform a retrospective analysis of adolescent patients with colorectal cancer, including clinicopathological characteristics and prognosis. Methods： The medical records of 11,503 patients diagnosed as colorectal cancer in Cancer Hospital, chinese Academy of Medical Sciences from January 1999 to December 2009 were retrospectively reviewed. Finally, 19 patients who were between 10 and 20 years old were selected as the study group. We summarized the clinicopathological characteristics, analyzed the association with prognosis and assessed the expression of MMR protein by immunohistochemical method. Results： The most common primary site was the right colon in 7 patients. Ten patients had Stage III colorectal cancer, 5 patients had Stage IV disease. Signet ring cell carcinoma was the most frequent pathological type （7/19）. Deficient MMR was identified in 2 patients. The 5-year survival rate and median survival time were 23.2% and 26 months. Distant metastasis was identified as an independent prognostic factor （P = 0.02）. Conclusions： Colorectal cancer in chinese adolescents was very rare. The chinese adolecents with colorectal cancer were frequently diagnosed in the right colon, as Stage Ⅲ/Ⅳdisease with signet ring cell carcinoma. The prognosis was relatively poor.

关键词： Adolescence Colorectal Cancer Prognosis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma

引用

chinese Medical Journal 2011年第19期124卷 2997-3002页

作者： yihebali chi REN Jian-hong YANG Lin CUI Cheng-xu LI Jun-ling WANG Jin-wan Department of Medical Oncology Cancer Hospital ＆ InstituteChinese Academy of Medical Sciences Beijing 100021 China

Background A phase Ⅲ trial involving docetaxel, cisplatin, and fluorouracil （DCF） in the treatment of advanced gastric cancer was shown to have superior efficacy compared to cisplatin and fluorouracil alone, but with a high rate of hematologic toxicity. To reduce toxicity while maintaining the efficacy of DCF, we reduced the doses of docetaxel （D） and cis-platinum （CDDP）, and administered 5-fluorouracil （5-FU） via a continuous intravenous （CIV） *** Chemotherapy-naive patients with gastric adenocarcinomas received D （60 mg/m2 1 hour on day 1）, CDDP （30 mg/m2on days 1 and 2）, and 5-FU （1500 mg·m-2·24 h-1 CIV on days 1 and 8 every 3 weeks）. The primary endpoint was the response *** Fourteen patients were enrolled. Based on the efficacy evaluation following at least 2 cycles of treatment, there was 7.1% complete remission （CR）, 71% partial remission （PR）, 14% stable disease （NC/SD）, and 7.1% progressive disease （PD）. The median survival time was 13 months. Nine patients （64%） had grade Ⅲ-Ⅳ neutropenia, and 4 patients （29%） had grade Ⅳ neutropenia, among whom 1 had grade Ⅳ neutropenia with grade Ⅲ nausea and *** The modified DCF regimen is highly active and has a favorable toxicity profile in chinese patients with gastric cancer.

关键词： gastric cancer modified DCF regimen docetaxel cis-platinum 5-fluorouracil

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A phase Ⅱ trial of oxaliplatin plus S-1 as a first-line chemotherapy for patients with advanced gastric cancer

引用

中华医学杂志(英文版) 2013年第18期126卷 3470-3474页

作者： YANG Lin SONG Yan ZHOU Ai-ping QIN Qiong chi yihebali HUANG Jing WANG Jin-wan Department of Medical Oncology Cancer Hospital and InstituteChinese Academy of Medical Sciences

Background Palliative chemotherapy has been shown to have a survival benefit for patients with recurrent or metastatic gastric *** conducted a Phase II trial to determine the efficacy and safety of S-1 plus oxaliplatin（SOX regimen）as first-line chemotherapy for patients with unresectable locally advanced or metastatic gastric *** Eligible patients had measurable lesions and no previous history of chemotherapy（except adjuvant chemotherapy）.Oxaliplatin was administered intravenously at a dose of 130 mg/m2on day 1.S-1 was administered orally in doses of 80,100,or 120 mg/d according to body surface areas of1.5 m2respectively;the total dose was divided into two daily doses on days *** were repeated every 3 weeks until disease progression or intolerable toxicity *** Forty-three patients were enrolled in the *** were assessable for efficacy and adverse *** objective response and disease control rates were 55.8%and 76.7%*** median follow-up time was 16.5 *** median progression-free survival time was 7 months（95%CI,5.8-8.2 months）and the median overall survival time was16.5 months（95%CI,9.7-23.3 months）.The one-year survival rate was 54.2%.Major adverse reactions were grade 3/4neutropenia（9.3%）and thrombocytopenia（20.9%）.Conclusion The SOX regimen with oxaliplatin at a dose of 130 mg/m2was found to be effective and safe as a first-line chemotherapy in chinese patients with advanced gastric cancer.

关键词： stomach neoplasms drug therapy oxaliplatin S-1

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib

引用

chinese Journal of Cancer Research 2023年第5期35卷 526-535页

作者： Jianwei Zhang Haibin Zhu Lin Shen Jie Li Xiaoyan Zhang Chunmei Bai Zhiwei Zhou Xianrui Yu Zhiping Li Enxiao Li Xianglin Yuan Wenhui Lou yihebali chi Nong Xu Yongmei Yin Yuxian Bai Tao Zhang Dianrong Xiu Jia Chen Shukui Qin Xiuwen Wang Yujie Yang Haoyun Shi Xian Luo Songhua Fan Weiguo Su Ming Lu Jianming Xu Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of Gastrointestinal OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of RadiologyPeking University Cancer Hospital&InstituteBeijing 100142China State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers Beijing Key Laboratory of Carcinogenesis and Translational ResearchDepartment of Gastrointestinal OncologyPeking University Cancer Hospital&InstituteBeijing 100142China Department of Medical Oncology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Department of Gastric Surgery State Key Laboratory of Oncology in South ChinaCollaborative Innovation Centre for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhou 510062China Department of Pancreatic and Hepatobiliary Surgery Fudan University Shanghai Cancer CenterShanghai 200032China Department of Abdominal Oncology West China HospitalSichuan UniversityChengdu 332001China Department of Medical Oncology the First Affiliated Hospital of Xi’an Jiaotong UniversityXi’an 710061China Department of Oncology Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Department of General Surgery Zhongshan Hospital of Fudan UniversityShanghai 200032China Department of Medical Oncology National Cancer Center/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Department of Medical Oncology the First Affiliated Hospital of Zhejiang UniversityHangzhou 310009China Department of Medical Oncology the First Affiliated Hospital of Nanjing Medical UniversityNanjing 210029China Department of Gastrointestinal Oncology Harbin Medical University Cancer HospitalHarbin 150081China Department of Oncology Union HospitalTongji Medical

Objective:Currently,pre-treatment prediction of patients with pancreatic neuroendocrine tumors with liver metastases(PNELM)receiving surufatinib treatment was *** objective was to examine the association between radiological characteristics and efficacy/***:We enrolled patients with liver metastases in the phase III,SANET-p trial(NCT02589821)and obtained contrast-enhanced computed tomography(CECT)*** and quantitative parameters including hepatic tumor margins,lesion volumes,enhancement pattern,localization types,and enhancement ratios were *** progression-free survival(PFS)and hazard ratio(HR)were calculated using Cox’s proportional hazard *** was analyzed by logistic-regression ***:Among 152 patients who had baseline CECT assessments and were included in this analysis,the surufatinib group showed statistically superior efficacy in terms of median PFS compared to placebo across various qualitative and quantitative *** the multivariable analysis of patients receiving surufatinib(N=100),those with higher arterial phase standardized enhancement ratio-peri-lesion(ASER-peri)exhibited longer PFS[HR=0.039;95%confidence interval(95%CI):0.003−0.483;P=0.012].Furthermore,patients with a high enhancement pattern experienced an improvement in the objective response ratio[31.3%vs.14.7%,odds ratio(OR)=3.488;95%CI:1.024−11.875;P=0.046],and well-defined tumor margins were associated with a higher disease control rate(DCR)(89.3%vs.68.2%,OR=4.535;95%CI:1.285−16.011;P=0.019)compared to poorlydefined ***:These pre-treatment radiological features,namely high ASER-peri,high enhancement pattern,and well-defined tumor margins,have the potential to serve as predictive markers of efficacy in patients with PNELM receiving surufatinib.

关键词： Neuroendocrine tumors liver metastases computed tomography surufatinib

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Finite-time Prescribed Performance Time-Varying Formation Control for Second-Order Multi-Agent Systems With Non-Strict Feedback Based on a Neural Network Observer

引用

IEEE/CAA Journal of Automatica Sinica 2024年第4期11卷 1039-1050页

作者： chi Ma Dianbiao Dong the School of Mechanical Engineering Northwestern Polytechnical UniversityXi’an 710072China

This paper studies the problem of time-varying formation control with finite-time prescribed performance for nonstrict feedback second-order multi-agent systems with unmeasured states and unknown *** eliminate nonlinearities,neural networks are applied to approximate the inherent dynamics of the *** addition,due to the limitations of the actual working conditions,each follower agent can only obtain the locally measurable partial state information of the leader *** address this problem,a neural network state observer based on the leader state information is ***,a finite-time prescribed performance adaptive output feedback control strategy is proposed by restricting the sliding mode surface to a prescribed region,which ensures that the closed-loop system has practical finite-time stability and that formation errors of the multi-agent systems converge to the prescribed performance bound in finite ***,a numerical simulation is provided to demonstrate the practicality and effectiveness of the developed algorithm.

关键词： Finite-time control multi-agent systems neural network prescribed performance control time-varying formation control

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

CAR-T在胃癌免疫治疗中的研究进展

引用

中国肿瘤临床 2022年第9期49卷 480-486页

作者：程浩依荷芭丽·迟周全应建明石素胜国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院病理科北京市100021 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肿瘤内科北京市100021

胃癌是最常见的恶性肿瘤之一,部分病例由于诊断较晚和治疗不佳,患者的整体生存期较差。近几年,嵌合抗原受体修饰T细胞(chimeric antigen receptor T cells,CAR-T)疗法在肿瘤治疗研究领域受到相当大的关注,且已在血液系统肿瘤中发挥了重... 详细信息

胃癌是最常见的恶性肿瘤之一,部分病例由于诊断较晚和治疗不佳,患者的整体生存期较差。近几年,嵌合抗原受体修饰T细胞(chimeric antigen receptor T cells,CAR-T)疗法在肿瘤治疗研究领域受到相当大的关注,且已在血液系统肿瘤中发挥了重要作用,但在实体肿瘤因受到靶点特异性,肿瘤微环境等因素影响而作用受限。尽管如此,各种临床前和临床实验已证实CAR-T细胞免疫治疗是胃癌一种有前景的治疗方法,并具有有别于其他实体瘤的优势,但是仍面临诸多挑战。本文将系统介绍CAR-T疗法在胃癌中的最新研究进展。

关键词：胃癌 CAR-T治疗生物学基础临床应用

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A phase II trial of oxaliplatin plus S-1 as a first-fine chemotherapy for patients with advanced gastric cancer

引用

chinese Medical Journal 2013年第18期 3470-3474页

作者： YANG Lin SONG Yan ZHOU Ai-ping QIN Qiong chi yihebali HUANG Jing WANG Jin-wan Department of Medical Oncology Cancer Hospital and Institute Chinese Academy of Medical Sciences Beijing 100021 China

Background Palliative chemotherapy has been shown to have a survival benefit for patients with recurrent or metastatic gastric cancer. We conducted a Phase II trial to determine the efficacy and safety of S-1 plus oxaliplatin （SOX regimen） as first-line chemotherapy for patients with unresectable locally advanced or metastatic gastric cancer. Methods Eligible patients had measurable lesions and no previous history of chemotherapy （except adjuvant chemotherapy）. Oxaliplatin was administered intravenously at a dose of 130 mg/m2 on day 1. S-1 was administered orally in doses of 80, 100, or 120 mg/d according to body surface areas of 〈1.25 m2, 1.25-1.5 m2, or 〉1.5 m2 respectively; the total dose was divided into two daily doses on days 1-14. Treatments were repeated every 3 weeks until disease progression or intolerable toxicity occurred. Results Forty-three patients were enrolled in the study. All were assessable for efficacy and adverse events. The objective response and disease control rates were 55.8% and 76.7% respectively. The median follow-up time was 16.5 months. The median progression-free survival time was 7 months （95% CI, 5.8-8.2 months） and the median overall survival time was 16.5 months （95% CI, 9.7-23.3 months）. The one-year survival rate was 54.2%. Major adverse reactions were grade 3/4 neutropenia （9.3%） and thrombocytopenia （20.9%）. Conclusion The SOX regimen with oxaliplatin at a dose of 130 mg/m2 was found to be effective and safe as a first-line chemotherapy in chinese patients with advanced gastric cancer.

关键词： stomach neoplasms drug therapy oxaliplatin S-1

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

抗体偶联药物治疗消化系统肿瘤的研究进展

引用

现代肿瘤医学 2022年第5期30卷 916-922页

作者：程浩依荷芭丽·迟石素胜国家癌症中心国家肿瘤临床医学研究中心中国医学科学院北京协和医学院肿瘤医院病理科北京100021 国家癌症中心国家肿瘤临床医学研究中心中国医学科学院北京协和医学院肿瘤医院肿瘤内科北京100021

消化系统肿瘤发病率和病死率较高,对于缺乏手术适应证及放疗、化疗效果不好的患者,亟需发展新型而高效的治疗手段。近年来,抗体-药物偶联物(antibody-drug conjugates,ADC)因其具有抗体药物的高选择性和细胞毒药物的高活性等优点而逐渐... 详细信息

消化系统肿瘤发病率和病死率较高,对于缺乏手术适应证及放疗、化疗效果不好的患者,亟需发展新型而高效的治疗手段。近年来,抗体-药物偶联物(antibody-drug conjugates,ADC)因其具有抗体药物的高选择性和细胞毒药物的高活性等优点而逐渐成为研究热点,在消化系统肿瘤的治疗中已取得一些成果,但是仍需面对诸多挑战。本文将对新进展进行简要综述。

关键词：抗体偶联药物消化系肿瘤生物学基础靶向治疗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：